Background
The Regents of the University of Minnesota held U.S. Patent No. 8,815,830, directed to phosphoramidate prodrugs of nucleoside derivatives — a class of antiviral and anticancer compounds. Phosphoramidate prodrugs are modified forms of nucleoside drugs designed to improve their absorption and efficacy inside cells. The technology is relevant to a class of drugs used to treat HIV, hepatitis C, and other viral infections, and has been the subject of significant commercial interest from pharmaceutical companies including Gilead Sciences.
Gilead Sciences, Inc. petitioned for inter partes review (IPR) challenging the ‘830 patent’s claims as anticipated by earlier prior art. The PTAB found the challenged claims unpatentable, and in doing so addressed the written description of the parent applications that the ‘830 patent claimed priority to. The University of Minnesota appealed, arguing the claims had adequate written description support in the parent patent applications. The Federal Circuit affirmed.
The Court’s Holding
The Federal Circuit affirmed the PTAB’s written description analysis. The court applied the well-established standard: a patent’s claims must be supported by a written description in the specification sufficient to show that the inventor “possessed” the full claimed invention at the time of filing. For broad genus claims in chemistry and biotechnology, this typically requires a representative number of specific species within the claimed genus, or structural features common to members of the genus.
The court found that the priority applications on which the University of Minnesota relied contained what it characterized as a “laundry list” of chemical moieties — long enumerated lists of possible functional groups and side chains — without adequately describing how those combinations related to a coherent class of compounds. The lists were “so long, and so interwoven” that even a skilled chemist could not readily determine which specific compounds fell within the claimed genera and subgenera. This type of disclosure — which merely catalogs chemical possibilities without describing what unifies the claimed class — is insufficient to support broad genus claims. The PTAB’s finding of unpatentability was affirmed.
Key Takeaways
- Broad chemical genus claims require written description support showing the inventor possessed the full scope of the genus — cataloging all possible chemical substituents in a “laundry list” does not satisfy this requirement.
- A written description is insufficient if it is so long and complex that a skilled artisan cannot determine which specific compounds fall within the claimed genus; the patent must convey the actual boundaries of the claimed class.
- For pharmaceutical and biotech patents claiming broad classes of compounds, the written description must identify structural features that make all claimed members recognizable as part of the same class — not just list every conceivable substituent.
- Priority claims can be defeated by written description arguments even in IPR proceedings if the patent specification that establishes the priority date does not adequately support the claims at issue.
Why It Matters
University of Minnesota v. Gilead Sciences is part of the Federal Circuit’s continuing effort to enforce meaningful written description requirements for broad chemical genus claims in pharmaceutical and biotech patents. The decision follows Amgen v. Sanofi’s similar restrictions on broad functional antibody claims and applies the same logic to small-molecule drug patents: claiming a vast universe of chemical compounds without describing the structural features that define the class does not constitute a sufficient written description. For universities, research institutions, and pharmaceutical companies prosecuting foundational drug patents, this ruling reinforces that early patent applications must specifically describe a representative set of compounds — or the structural features that unify the claimed class — to support subsequent broad genus claims.
The case also highlights the strategic use of IPR to challenge pioneer drug patents held by academic institutions. As university technology transfer offices increasingly assert foundational chemistry patents against large pharmaceutical companies, this decision shows that even important drug-development patents can be vulnerable to written description challenges if the underlying patent applications were not drafted with sufficient chemical specificity.